{"id":868965,"date":"2025-07-11T17:12:52","date_gmt":"2025-07-11T21:12:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/"},"modified":"2025-07-11T17:12:52","modified_gmt":"2025-07-11T21:12:52","slug":"capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/","title":{"rendered":"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura<\/b><\/p>\n<p>OAKLAND, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nShares of Capricor Therapeutics, Inc. plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejected the company\u2019s Biologics License Application for its lead cell therapy candidate, Deramiocel, claiming that the application \u201cdoes not meet the statutory requirement for substantial evidence of effectiveness\u201d and lacks \u201ccertain outstanding items.\u201d Gibbs Mura is investigating a potential <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.classlawgroup.com%2Fsecurities-fraud%2Fstock%2Fcapricor-therapeutics-inc-stock-lawsuit&amp;esheet=54289468&amp;newsitemid=20250711471343&amp;lan=en-US&amp;anchor=Capricor+Therapeutics%2C+Inc.+%28NASDAQ%3A+CAPR%29+Securities+Class+Action+Lawsuit&amp;index=1&amp;md5=0cce6e11cb3b6bda54ef155bad86ea68\">Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Class Action Lawsuit<\/a> on behalf of shareholders who lost money in Capricor Therapeutics, Inc.<\/p>\n<p><b>What Should Capricor Therapeutics, Inc. Investors Do?<\/b><\/p>\n<p><b>If you invested in Capricor Therapeutics, Inc., visit our <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.classlawgroup.com%2Fsecurities-fraud%2Fstock%2Fcapricor-therapeutics-inc-stock-lawsuit&amp;esheet=54289468&amp;newsitemid=20250711471343&amp;lan=en-US&amp;anchor=Capricor+Therapeutics%2C+Inc.+Investigation+webpage&amp;index=2&amp;md5=5c9efe0272488200c7d405b7810bccf7\"><b>Capricor Therapeutics, Inc. Investigation webpage<\/b><\/a><b> or call us at<\/b><b>(888) 410-2925 <\/b>to get more information about how you may be able to recover your losses. Our investigation concerns whether Capricor Therapeutics, Inc. has violated federal securities laws by providing false or misleading statements to investors.<\/p>\n<p><b>What is the Capricor Therapeutics, Inc. (CAPR) Lawsuit Investigation About?<\/b><\/p>\n<p>\nOn July 11, 2025, Capricor Therapeutics announced that the FDA rejected the company\u2019s Biologics License Application (BLA) for its cell therapy candidate, Deramiocel, citing that the application \u201cdoes not meet the statutory requirement for substantial evidence of effectiveness\u201d and lacks \u201ccertain outstanding items.\u201d The FDA\u2019s Complete Response Letter specified that the deficiencies were in the BLA\u2019s Chemistry, Manufacturing, and Controls section, and emphasized a need for additional clinical data.<\/p>\n<p>\nFollowing this news, shares of Capricor Therapeutics, Inc. plunged over 30% in intraday trading on July 11, 2025, causing harm to investors.<\/p>\n<p>\nPreviously, on May 5, 2025, Capricor announced that the FDA \u201cconfirmed its intent to hold an advisory committee meeting\u201d following the completion of a mid-cycle review meeting for the company\u2019s BLA for Deramiocel. Following the announcement, Capricor\u2019s stock fell over 29% on May 6, 2025. Then, on June 20, 2025, STAT reported that the director of the FDA\u2019s Center for Biologics Evaluation and Research canceled the advisory committee meeting regarding Deramiocel, due to being \u201cskeptical of the treatment.\u201d In the wake of the report, Capricor\u2019s stock fell over 30% on June 20, 2025.<\/p>\n<p><b>About Gibbs Mura<\/b><\/p>\n<p>\nGibbs Mura represents investors nationwide in <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.classlawgroup.com%2Fsecurities-fraud%2Finvestment%2F&amp;esheet=54289468&amp;newsitemid=20250711471343&amp;lan=en-US&amp;anchor=securities+litigation&amp;index=3&amp;md5=a1f370eecbe84091dbd4ee6698abfecd\">securities litigation<\/a>. The firm has recovered over a billion dollars for its clients against some of the world\u2019s largest corporations, and our attorneys have received numerous honors for their work, including \u201cBest Lawyers in America,\u201d \u201cTop Plaintiff Lawyers in California,\u201d \u201cCalifornia Lawyer Attorney of the Year,\u201d \u201cClass Action Practice Group of the Year,\u201d \u201cConsumer Protection MVP,\u201d and \u201cTop Women Lawyers in California.\u201d<\/p>\n<p><i>This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250711471343\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250711471343\/en\/<\/a><\/span><\/p>\n<p>\nCATHERINE CONROY<br \/>\n<br \/>PHONE: 510.350.9705<br \/>\n<br \/>EMAIL: <a rel=\"nofollow\" href=\"mailto:CRC@CLASSLAWGROUP.COM\">CRC@CLASSLAWGROUP.COM<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250711471343\/en\/2521437\/3\/GMLG_securities_press_release_logo_v2.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura OAKLAND, Calif.&#8211;(BUSINESS WIRE)&#8211; Shares of Capricor Therapeutics, Inc. plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejected the company\u2019s Biologics License Application for its lead cell therapy candidate, Deramiocel, claiming that the application \u201cdoes not meet the statutory requirement for substantial evidence of effectiveness\u201d and lacks \u201ccertain outstanding items.\u201d Gibbs Mura is investigating a potential Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Class Action Lawsuit on behalf of shareholders who lost money in Capricor Therapeutics, Inc. What Should Capricor Therapeutics, Inc. Investors Do? If you invested in Capricor Therapeutics, Inc., visit our Capricor Therapeutics, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-868965","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura OAKLAND, Calif.&#8211;(BUSINESS WIRE)&#8211; Shares of Capricor Therapeutics, Inc. plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejected the company\u2019s Biologics License Application for its lead cell therapy candidate, Deramiocel, claiming that the application \u201cdoes not meet the statutory requirement for substantial evidence of effectiveness\u201d and lacks \u201ccertain outstanding items.\u201d Gibbs Mura is investigating a potential Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Class Action Lawsuit on behalf of shareholders who lost money in Capricor Therapeutics, Inc. What Should Capricor Therapeutics, Inc. Investors Do? If you invested in Capricor Therapeutics, Inc., visit our Capricor Therapeutics, &hellip; Continue reading &quot;Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-11T21:12:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura\",\"datePublished\":\"2025-07-11T21:12:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/\"},\"wordCount\":492,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/\",\"name\":\"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-07-11T21:12:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/","og_locale":"en_US","og_type":"article","og_title":"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura - Market Newsdesk","og_description":"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura OAKLAND, Calif.&#8211;(BUSINESS WIRE)&#8211; Shares of Capricor Therapeutics, Inc. plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejected the company\u2019s Biologics License Application for its lead cell therapy candidate, Deramiocel, claiming that the application \u201cdoes not meet the statutory requirement for substantial evidence of effectiveness\u201d and lacks \u201ccertain outstanding items.\u201d Gibbs Mura is investigating a potential Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Class Action Lawsuit on behalf of shareholders who lost money in Capricor Therapeutics, Inc. What Should Capricor Therapeutics, Inc. Investors Do? If you invested in Capricor Therapeutics, Inc., visit our Capricor Therapeutics, &hellip; Continue reading \"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-11T21:12:52+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura","datePublished":"2025-07-11T21:12:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/"},"wordCount":492,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/","name":"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-07-11T21:12:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250711471343r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-inc-nasdaq-capr-securities-fraud-investigation-capr-investors-urged-to-contact-award-winning-firm-gibbs-mura\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=868965"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868965\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=868965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=868965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=868965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}